Search

Your search keyword '"Lau, C. S."' showing total 520 results
Start Over Author "Lau, C. S."
520 results on '"Lau, C. S."'

1. AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK

Author

Sbarigia, U., primary, Zazzetti, F., additional, Lewi, M., additional, Van Speybroeck, M., additional, Simon, T. A., additional, Li, G., additional, Sonmez, R., additional, Carter, C., additional, Karyekar, C. S., additional, Noel, W., additional, Ugarte-Gil, M. F., additional, Gamboa-Cardenas, R. V., additional, Pons-Estel, G., additional, Borba, E. F., additional, Massardo, L., additional, Aroca Martínez, G., additional, Muñoz Louis, R., additional, Moreno Alvarez, M., additional, García De La Torre, I., additional, Acosta Colmán, I., additional, Mora Trujillo, C., additional, Danza, Á., additional, Michaud, K., additional, Katz, P., additional, Kandane-Rathnayake, R., additional, Morand, E., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, LI, Z., additional, Sockalingam, S., additional, Harigai, M., additional, Zhang, Z., additional, Basnayake, D., additional, Chan, M., additional, Takeuchi, T., additional, Bae, S. C., additional, Goldblatt, F., additional, ’neill, S. O, additional, Ng, K. P. L., additional, Tugnet, N., additional, Kumar, S., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Hoi, A., additional, Nikpour, M., additional, Rúa-Figueroa, Í., additional, Pego-Reigosa, J. M., additional, Galindo-Izquierdo, M., additional, Calvo Alén, J., additional, Fernández-Nebro, A., additional, Menor-Almagro, R., additional, and Lavie, F., additional

Published
2024
Full Text
View/download PDF

2. POS0152 PREVALENCE AND OUTCOMES OF SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): OBSERVATIONS FROM A MULTINATIONAL COHORT

Author

Kandane-Rathnayake, R., primary, Louthrenoo, W., additional, Lau, C. S., additional, Hamijoyo, L., additional, Cho, J., additional, Lateef, A., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, Chen, Y. H., additional, Oon, S., additional, Chan, M., additional, Sockalingam, S., additional, Hao, Y., additional, Zhang, Z., additional, Bae, S. C., additional, Kikuchi, J., additional, Takeuchi, T., additional, Katsumata, Y., additional, Harigai, M., additional, Basnayake, D., additional, Goldblatt, F., additional, ’neill, S. O, additional, Ng, K. P. L., additional, Tugnet, N., additional, Kumar, S., additional, Law Hui Nee, A., additional, Tee, C., additional, Tee, M., additional, Ohkubo, N., additional, Jullion, A., additional, Shisha, T., additional, Tanaka, Y., additional, Golder, V., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E., additional

Published
2024
Full Text
View/download PDF

6. Intermanufacturer assessment of diagnostic performance of angiogenic ratio vs glycosylated fibronectin in women with suspected pre‐eclampsia.

Author

Wah, I. Y. M., Sahota, D. S., Wong, N. K. L., Lee, N. M. W., Liu, C. J., Lau, C. S. L., Leung, H. H. Y., and Poon, L. C.

Subjects
PLACENTAL growth factor, EAST Asians, HYPERTENSION in pregnancy, FIBRONECTINS, GESTATIONAL age, ECLAMPSIA
Abstract

Objective: To compare the diagnostic performance of different manufacturers' immunoassays for the soluble fms‐like tyrosine kinase‐1 (sFlt‐1)‐to‐placental growth factor (PlGF) ratio with that of a point‐of‐care (PoC) test for glycosylated fibronectin (GlyFn) in women with suspected pre‐eclampsia (PE). Methods: This was a prospective, single‐center, double‐blinded, non‐interventional study of East Asian women with a singleton pregnancy who presented with hypertension with or without clinical features of PE after 20 weeks' gestation between January 2020 and March 2022. Maternal serum samples were collected at the time of presentation, and subsequent management followed the departmental protocol, based on gestational age, severity of hypertension, fetal condition and presence of severe PE features. Women diagnosed with PE at presentation were excluded. PE was diagnosed according to the 2018 International Society for the Study of Hypertension in Pregnancy classification. Levels of sFlt‐1 and PlGF were measured using the Cobas e411 (Roche Diagnostics), BRAHMS KRYPTOR (ThermoFisher Scientific) and iMAGIN 1800 (Ningbo Aucheer) platforms. GlyFn levels were measured using the Lumella™ GlyFn PoC test (DiabetOmics Inc.). The predictive performance of each test to rule out PE within 7 days and rule in PE within 28 days from the date of presentation was assessed. Based on the PROGNOSIS study, a sFlt‐1/PlGF ratio of ≤ 38 on the Roche platform was used to predict the absence of PE within 7 days. The sFlt‐1/PlGF ratio was classified as high or low using platform‐specific thresholds equivalent to a Roche sFlt‐1/PlGF ratio of 38, which were derived using Passing–Bablok regression. GlyFn was categorized as high or low using two reported clinical management thresholds (263 μg/mL and 510 μg/mL). Results: Overall, 236 women with suspected PE were included, of whom 70 (29.7%) were diagnosed with PE; 36 (51.4%) and 70 (100%) developed PE within 7 days and 28 days, respectively. Eighty‐eight (37.3%) women had a sFlt‐1/PlGF ratio of > 38 on the Roche platform, 79 (33.5%) women had a sFlt‐1/PlGF ratio of > 55 on the KRYPTOR platform and 96 (40.7%) women had a sFlt‐1/PlGF ratio of > 40 on the iMAGIN 1800 platform. Furthermore, 62 (26.3%) and four (1.7%) women had a GlyFn level of > 263 μg/mL and > 510 μg/mL, respectively. The negative predictive value (NPV) of the sFlt‐1/PlGF ratio measured on the Roche, KRYPTOR and iMAGIN 1800 platforms to rule out PE within 7 days after presentation was 83.3%, 82.0% and 82.9%, respectively, while that for GlyFn > 263 μg/mL and > 510 μg/mL was 82.6% and 70.4%, respectively. The corresponding positive predictive values (PPV) to rule in PE within 28 days after presentation were 50.5%, 52.3% and 46.7%, respectively, for the sFlt‐1/PlGF ratio, and 35.4% and 50.0%, respectively, for GlyFn > 263 μg/mL and > 510 μg/mL. Conclusions: The predictive performance of different manufacturers' assays for the sFlt‐1/PlGF ratio to rule in and rule out PE were similar once standardized to a common threshold. Our findings suggest that the sFlt‐1/PlGF ratio and GlyFn using a cut‐off of 263 μg/mL can both be utilized to rule out PE within 7 days after assessment, with a moderate NPV. The PPV for ruling in PE within 28 days remains poor. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. A conserved protein interaction network involving the yeast MAP kinases Fus3 and Kss1

Author

Kusari, A B, Molina, D M, Sabbagh, W, Lau, C S, and Bardwell, Lee

Subjects
mitogen-activated protein kinases, signal transduction, phosphorylation, binding sites, protein binding
Abstract

The Saccharomyces cerevisiae mitogen-activated protein kinases (MAPKs) Fus3 and Kss1 bind to multiple regulators and substrates. We show that mutations in a conserved docking site in these MAPKs (the CD/7rn region) disrupt binding to an important subset of their binding partners, including the Ste7 MAPK kinase, the Ste5 adaptor/scaffold protein, and the Dig1 and Dig2 transcriptional repressors. Supporting the possibility that Ste5 and Ste7 bind to the same region of the MAPKs, they partially competed for Fus3 binding. In vivo, some of the MAPK mutants displayed reduced Ste7-dependent phosphorylation, and all of them exhibited multiple defects in mating and pheromone response. The Kss1 mutants were also defective in Kss1-imposed repression of Ste12. We conclude that MAPKs contain a structurally and functionally conserved docking site that mediates an overall positively acting network of interactions with cognate docking sites on their regulators and substrates. Key features of this interaction network appear to have been conserved from yeast to humans.

Published
2004

10. POS1481 INFORMING TRIAL MEASUREMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: FREQUENCY OF DOMAIN-SPECIFIC DISEASE ACTIVITY IN A MULTI-NATIONAL OBSERVATIONAL COHORT

Author

Connelly, K., primary, Kandane-Rathnayake, R., additional, Golder, V., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Oon, S., additional, Bae, S. C., additional, Goldblatt, F., additional, O’neill, S., additional, Ng, K., additional, Law, A., additional, Basnayake, B., additional, Tugnet, N., additional, Kumar, S., additional, Tee, C., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E. F., additional

Published
2023
Full Text
View/download PDF

11. OP0048 RISK OF FLARE AND DAMAGE ACCRUAL AFTER TAPERING GLUCOCORTICOIDS IN SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Author

Katsumata, Y., primary, Inoue, E., additional, Harigai, M., additional, Kandane-Rathnayake, R., additional, Louthrenoo, W., additional, Hoi, A., additional, Golder, V., additional, Lau, C. S., additional, Cho, J., additional, Lateef, A., additional, Chen, Y. H., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Hamijoyo, L., additional, Li, Z., additional, Sockalingam, S., additional, Navarra, S., additional, Zamora, L., additional, Hao, Y., additional, Zhang, Z., additional, Chan, M., additional, Oon, S., additional, Ng, K., additional, Kikuchi, J., additional, Takeuchi, T., additional, Goldblatt, F., additional, O’neill, S., additional, Tugnet, N., additional, Law, A., additional, Bae, S. C., additional, Tanaka, Y., additional, Ohkubo, N., additional, Kumar, S., additional, Nikpour, M., additional, and Morand, E. F., additional

Published
2023
Full Text
View/download PDF

13. OP0226 ATTAINMENT OF LUPUS LOW DISEASE ACTIVITY STATE EXCLUSIVE OF REMISSION IS PROTECTIVE AGAINST ADVERSE OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS

Author

Kandane-Rathnayake, R., primary, Golder, V., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Basnayake, B., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Oon, S., additional, Bae, S. C., additional, O’neill, S., additional, Goldblatt, F., additional, Ng, K., additional, Law, A., additional, Tugnet, N., additional, Kumar, S., additional, Tee, M., additional, Tee, C., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E. F., additional

Published
2023
Full Text
View/download PDF

15. POS0121 ASSOCIATION OF LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT WITH REDUCED ORGAN DAMAGE AND FLARE IN SLE PATIENTS WITH HIGH DISEASE ACTIVITY

Author

Kandane-Rathnayake, R., primary, Golder, V., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, Li, Z., additional, An, Y., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Basnayake, B., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Bae, S. C., additional, Oon, S., additional, O’neill, S., additional, Goldblatt, F., additional, Gibson, K., additional, Ng, K., additional, Law, A., additional, Tugnet, N., additional, Kumar, S., additional, Tee, C., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Morand, E. F., additional, and Hoi, A., additional

Published
2022
Full Text
View/download PDF

16. OP0142 COMPARISON OF ATTAINMENT AND PROTECTIVE EFFECTS OF THE LUPUS LOW DISEASE ACTIVITY STATE IN PATIENTS WITH NEWLY DIAGNOSED VERSUS ESTABLISHED SLE - A MULTICENTRE PROSPECTIVE STUDY

Author

Golder, V., primary, Kandane-Rathnayake, R., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, An, Y., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Basnayake, B., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Bae, S. C., additional, O’neill, S., additional, Goldblatt, F., additional, Oon, S., additional, Gibson, K., additional, Ng, K., additional, Law, A., additional, Tugnet, N., additional, Kumar, S., additional, Tee, C., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E. F., additional

Published
2022
Full Text
View/download PDF

18. Aplar rheumatoid arthritis treatment recommendations: APL15-0692

Author

LAU, C S, CHIA, F, HARRISON, A, HSIEH, T Y, JAIN, R, JUNG, S M, KISHIMOTO, K, KUMAR, A, LEONG, K P, LI, Z G, LICHAUCO, J J, LOUTHRENOO, W, LUO, S F, PARK, S H, NASH, P, NG, C T, SUWANNALAI, P, WIJAYA, L K, YANG, Y, YAMAMOTO, K, and YEAP, S S

Published
2015

24. POS0028 DEFINING THE PREVALENCE OF UNMET NEED IN SLE: DATA FROM A LARGE MULTINATIONAL LONGITUDINAL SLE COHORT

Author

Kandane-Rathnayake, R., primary, Louthrenoo, W., additional, Hoi, A., additional, Golder, V., additional, Chen, Y. H., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Lateef, A., additional, Cho, J., additional, Hamijoyo, L., additional, Lau, C. S., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, An, Y., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Kikuchi, J., additional, Takeuchi, T., additional, Basnayake, B., additional, Goldblatt, F., additional, Chan, M., additional, Ng, K., additional, Bae, S. C., additional, Oon, S., additional, O’neill, S., additional, Gibson, K., additional, Kumar, S., additional, Tugnet, N., additional, Tanaka, Y., additional, Nikpour, M., additional, and Morand, E. F., additional

Published
2021
Full Text
View/download PDF

35. AB0384 MEDICATION USE IN SYSTEMIC LUPUS ERYTHEMATOSUS – DATA FROM A MULTICENTRE COHORT STUDY

Author

Kandane-Rathnayake, R., primary, Louthrenoo, W., additional, Luo, S. F., additional, Wu, Y. J., additional, Chen, Y. H., additional, Golder, V., additional, Lateef, A., additional, Cho, J., additional, Navarra, S., additional, Zamora, L., additional, Hamijoyo, L., additional, Sockalingam, S., additional, An, Y., additional, Li, Z., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Goldblatt, F., additional, O’neill, S., additional, Karyekar, C., additional, Lofland, J. H., additional, Bae, S. C., additional, Lau, C. S., additional, Hoi, A., additional, Nikpour, M., additional, and Morand, E. F., additional

Published
2020
Full Text
View/download PDF

36. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review

Author

Leung, T. Y. M., primary, Chan, A. Y. L., additional, Chan, E. W., additional, Chan, V. K. Y., additional, Chui, C. S. L., additional, Cowling, B. J., additional, Gao, L., additional, Ge, M. Q., additional, Hung, I. F. N., additional, Ip, M. S. M., additional, Ip, P., additional, Lau, K. K., additional, Lau, C. S., additional, Lau, L. K. W., additional, Leung, W. K., additional, Li, X., additional, Luo, H., additional, Man, K. K. C., additional, Ng, V. W. S., additional, Siu, C. W., additional, Wan, E. Y. F., additional, Wing, Y. K., additional, Wong, C. S. M., additional, Wong, K. H. T., additional, and Wong, I. C. K., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results